Comparison · NCT02173769-sae
Spiriva Respimat + Striverdi Respimat vs Spiriva 18 mcg + Striverdi Respimat: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Spiriva Respimat + Striverdi Respimat vs Spiriva 18 mcg + Striverdi Respimat: serious adverse events. Trial comparisons, record NCT02173769-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02173769-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0231 | 0.0162 | 0.0328 | wilson | |
| Risk in group 2 | 0.0214 | 0.0123 | 0.0371 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00168 | -0.0154 | 0.015 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.556 | 2.09 | log | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.549 | 2.13 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Spiriva Respimat + Striverdi Respimat than on Spiriva 18 mcg + Striverdi Respimat | 594 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Spiriva Respimat + Striverdi Respimat | Patients with moderate to severe chronic obstructive pulmonary disease (COPD) and treated with Spiriva Respimat plus Striverdi Respimat | 30 | 1,298 | EG000 |
| Group 2 | Spiriva 18 mcg + Striverdi Respimat | Patients with moderate to severe chronic obstructive pulmonary disease (COPD) and treated with Spiriva 18 microgram plus Striverdi Respimat | 12 | 560 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From start of study until 21 days after permanent discontinuation of study therapy or end of study, up to 9 weeks
Source ClinicalTrials.gov
Trial
- Title
- Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy
- NCT number
- NCT02173769
- Phases
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Spiriva® Respimat®, Striverdi® Respimat®
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2016-04-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02173769?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02173769-sae